BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sánchez ARP, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol 2022. [PMID: 35039665 DOI: 10.1038/s41584-021-00739-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 El Miedany Y, Kamel NS, Abu-zaid MH, El Hadidi K, Mahmoud GA, Sarhan E, El Gaafary M, Abdel-nasser A, Abualfadl EM, Azim AA, Fathi NA, Mokbel A, Hassan W, Tabra SAA, Eissa M, Mortada M, Fouad NA, Elnemr R, Mansour AE, Elaraby I, Medhat BM, Mohamed SS, Abdelradi ER, Ibrahim RA, Saber S. Egyptian evidence-based consensus on clinical practice recommendations for the management of lupus nephritis. Egypt Rheumatol Rehabil 2022;49:48. [DOI: 10.1186/s43166-022-00146-w] [Reference Citation Analysis]
2 Hao X, Zhang H, Liu R, Che J, Zhang D, Liang J, Sun L. Red blood cell membrane functionalized biomimetic nanoparticles for systemic lupus erythematosus treatment. Materials Today Advances 2022;16:100294. [DOI: 10.1016/j.mtadv.2022.100294] [Reference Citation Analysis]
3 Parodis I. Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus. The Lancet Rheumatology 2022. [DOI: 10.1016/s2665-9913(22)00358-7] [Reference Citation Analysis]
4 Smith EM, Lythgoe H, Hedrich CM. Current views on lupus in children. Current Opinion in Rheumatology 2022;Publish Ahead of Print. [DOI: 10.1097/bor.0000000000000913] [Reference Citation Analysis]
5 Ceccarelli F, Govoni M, Piga M, Cassone G, Cantatore FP, Olivieri G, Cauli A, Favalli EG, Atzeni F, Gremese E, Iannone F, Caporali R, Sebastiani M, Ferraccioli GF, Lapadula G, Conti F. Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium. JCM 2022;11:6016. [DOI: 10.3390/jcm11206016] [Reference Citation Analysis]
6 Kandane-rathnayake R, Golder V, Louthrenoo W, Chen Y, Cho J, Lateef A, Hamijoyo L, Luo S, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake BMDB, Chan M, Kikuchi J, Takeuchi T, Bae S, Oon S, O'neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Yu D, Karyekar CS, Sing Lau C, Monk JA, Nikpour M, Hoi A, Morand EF. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study. The Lancet Rheumatology 2022. [DOI: 10.1016/s2665-9913(22)00304-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G, Schett G. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. [DOI: 10.1038/s41591-022-02017-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zhan S, Liu C, Li N, Li T, Tian Z, Zhao M, Wu D, Chen M, Zeng Z, Zhuang X. Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis. Therap Adv Gastroenterol 2022;15:17562848221116666. [PMID: 36082178 DOI: 10.1177/17562848221116666] [Reference Citation Analysis]
9 Gomez A, Parodis I. Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature. Autoimmun Rev 2022;21:103188. [PMID: 36089249 DOI: 10.1016/j.autrev.2022.103188] [Reference Citation Analysis]
10 Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: history and modernity. Naučno-praktičeskaâ revmatologiâ 2022;60:397-412. [DOI: 10.47360/1995-4484-2022-397-412] [Reference Citation Analysis]
11 Frostegård J. Systemic lupus erythematosus and cardiovascular disease. J Intern Med 2022. [PMID: 35982610 DOI: 10.1111/joim.13557] [Reference Citation Analysis]
12 Navarini L, Vomero M, Di Donato S, Currado D, Berardicurti O, Marino A, Bearzi P, Biaggi A, Ferrito M, Ruscitti P, Fava M, Leuti A, Cipriani P, Maccarrone M, Giacomelli R. 2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus. Biomedicines 2022;10:1675. [DOI: 10.3390/biomedicines10071675] [Reference Citation Analysis]
13 Bertsias G. Recommendations for Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America 2022. [DOI: 10.1016/j.rdc.2022.05.001] [Reference Citation Analysis]